ArticleVirologica Sinica2025
Oncolytic HSV-1 expressing GM-CSF and IL-12 enhances anti-tumor efficacy in immunocompetent murine melanoma model.
Article in Virologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preclinical evaluation of triple-mutated oncolytic herpes virus expressing fusion-type interleukin 12 for malignant melanoma.Molecular therapy. Oncology · 2026Article
- Rearming mesenchymal stem cells with engineering strategies to combat cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic virus therapy is a promising strategy for cancer treatment. Herpes simplex virus type 1 (HSV-1) has been successfully used in oncolytic virotherapy. In the present research, we applied an HSV-1 synthetic genomics platform to construct two oncolytic viruses, oHSV-1.1 and oHSV-1.2. oHSV-1.1 had the virulence gene ICP34.5 and ICP47 deleted for attenuation, and oHSV-1.2 was additionally armed with murine granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin-12 (IL-12). The oncolytic viruses were evaluated in vitro and in an immunocompetent murine melanoma model. The animal experiments confirmed that both oncolytic viruses displayed antitumor efficacy, including inhibiting tumor growth and prolonging overall survival. Compared with oHSV-1.1, oHSV-1.2 demonstrated superior tumor growth suppression and enhanced antitumor efficacies, as evidenced by increased tumor cell apoptosis, cytotoxic T cells and macrophages infiltration, IFN-γ production, and upregulation of inflammatory-related gene expression. Our research highlights the potential of oncolytic HSV-1 expressing both GM-CSF and IL-12 for melanoma therapy, and provides a promising strategy for further development of oncolytic virotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.